ATE224715T1 - Formulierung von d-threo methylphenidat mit verzögerter freisetzung - Google Patents

Formulierung von d-threo methylphenidat mit verzögerter freisetzung

Info

Publication number
ATE224715T1
ATE224715T1 AT96924083T AT96924083T ATE224715T1 AT E224715 T1 ATE224715 T1 AT E224715T1 AT 96924083 T AT96924083 T AT 96924083T AT 96924083 T AT96924083 T AT 96924083T AT E224715 T1 ATE224715 T1 AT E224715T1
Authority
AT
Austria
Prior art keywords
release formulation
sustained release
threo methylphenidate
threo
methylphenidate
Prior art date
Application number
AT96924083T
Other languages
English (en)
Inventor
Helen Frances Baker
Julian Clive Gilbert
Original Assignee
Medeva Europ Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Europ Ltd filed Critical Medeva Europ Ltd
Application granted granted Critical
Publication of ATE224715T1 publication Critical patent/ATE224715T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
AT96924083T 1995-07-14 1996-07-15 Formulierung von d-threo methylphenidat mit verzögerter freisetzung ATE224715T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9514451.5A GB9514451D0 (en) 1995-07-14 1995-07-14 Sustained-release formulation
PCT/GB1996/001690 WO1997003673A1 (en) 1995-07-14 1996-07-15 Sustained-release formulation of d-threo-methylphenidate

Publications (1)

Publication Number Publication Date
ATE224715T1 true ATE224715T1 (de) 2002-10-15

Family

ID=10777685

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96924083T ATE224715T1 (de) 1995-07-14 1996-07-15 Formulierung von d-threo methylphenidat mit verzögerter freisetzung

Country Status (17)

Country Link
US (1) US5874090A (de)
EP (1) EP0841928B1 (de)
JP (1) JPH11509228A (de)
KR (1) KR100481416B1 (de)
AT (1) ATE224715T1 (de)
AU (1) AU702371B2 (de)
CA (1) CA2223643C (de)
CZ (1) CZ285956B6 (de)
DE (1) DE69623970T2 (de)
DK (1) DK0841928T3 (de)
ES (1) ES2186790T3 (de)
GB (1) GB9514451D0 (de)
HU (1) HU224314B1 (de)
MX (1) MX9800394A (de)
PT (1) PT841928E (de)
SK (1) SK281569B6 (de)
WO (1) WO1997003673A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
WO1997003671A1 (en) 1995-07-14 1997-02-06 Medeva Europe Limited Composition comprising d-threo-methylphenidate and another drug
US7081238B2 (en) * 1995-11-03 2006-07-25 The President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6355656B1 (en) * 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
JP2002541092A (ja) * 1999-04-06 2002-12-03 ファーマクエスト・リミテッド メチルフェニデートのパルス性送達のための薬学的投薬形態
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US7553478B2 (en) * 1999-05-12 2009-06-30 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
US20100143248A1 (en) * 1999-06-28 2010-06-10 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
MXPA02004293A (es) 1999-10-29 2002-10-31 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada..
JP3856283B2 (ja) * 2000-02-14 2006-12-13 シャープ株式会社 固体撮像装置および撮像装置の駆動方法
US6221883B1 (en) 2000-04-12 2001-04-24 Ross Baldessarini Method of dopamine inhibition using l-threo-methylphenidate
DE60027282T2 (de) * 2000-06-17 2007-04-12 Pharmaquest Ltd., Hamilton Verwendung von l-threo-methylphenidate zur Herstellung eines Medikaments für die Behandlung von Depression
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
CN100518827C (zh) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US6638533B2 (en) 2002-01-03 2003-10-28 George Krsek Pulse dosage formulations of methylphenidate and method to prepare same
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
CN101076248A (zh) * 2004-12-09 2007-11-21 塞尔基因公司 使用d－苏型哌甲酯的治疗
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
AU2006235483B2 (en) * 2005-04-12 2010-11-25 Elan Pharma International Limited Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
EP2428205B1 (de) 2006-03-16 2012-10-03 Tris Pharma, Inc. Modifizierte Freisetzungsformulierungen mit Arznei-Ion-Austausch-Harzkomplexen
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
WO2011020032A2 (en) * 2009-08-13 2011-02-17 Kudco Ireland, Ltd. Pharmaceutical dosage form
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
WO2012129551A1 (en) 2011-03-23 2012-09-27 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
DK2884961T3 (en) 2012-08-15 2019-04-23 Tris Pharma Inc METHYLPHENIDATE TABLE WITH EXTENDED RELEASE
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
KR102174787B1 (ko) 2018-11-14 2020-11-05 호서대학교 산학협력단 재사용이 가능한 다용도 로드 및 이를 갖는 약물 투여기
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507631A (en) * 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
US2957880A (en) * 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US2838519A (en) * 1953-12-23 1958-06-10 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4192827A (en) * 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders

Also Published As

Publication number Publication date
US5874090A (en) 1999-02-23
SK2998A3 (en) 1998-07-08
EP0841928A1 (de) 1998-05-20
HU224314B1 (hu) 2005-07-28
PT841928E (pt) 2002-12-31
SK281569B6 (sk) 2001-05-10
EP0841928B1 (de) 2002-09-25
AU702371B2 (en) 1999-02-18
HUP9802252A3 (en) 1999-04-28
CZ285956B6 (cs) 1999-12-15
CA2223643C (en) 2003-12-23
KR100481416B1 (ko) 2005-07-29
DK0841928T3 (da) 2003-01-27
HUP9802252A2 (hu) 1999-01-28
WO1997003673A1 (en) 1997-02-06
AU6466196A (en) 1997-02-18
MX9800394A (es) 1998-09-30
JPH11509228A (ja) 1999-08-17
KR19990028984A (ko) 1999-04-15
ES2186790T3 (es) 2003-05-16
DE69623970D1 (de) 2002-10-31
GB9514451D0 (en) 1995-09-13
CZ9298A3 (cs) 1998-06-17
CA2223643A1 (en) 1997-02-06
DE69623970T2 (de) 2003-06-05

Similar Documents

Publication Publication Date Title
ATE224715T1 (de) Formulierung von d-threo methylphenidat mit verzögerter freisetzung
NO20000935L (no) Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei
ATE207897T1 (de) Piperidinderivate als neurokininantagonisten
AR001795A1 (es) Compuestos inhibidores de la proteina de transferencia trigliceridos microsomales proceso para prevenir y tratar ateroesclerosis y/o reducir los nive les sericos de trigliceridos colesterol y lipidos procedimiento para prepararlos y compuestos intermediarios de aplicación en dicho procedimiento
DE69621777T2 (de) Formen von paroxetin hydrochlorid
DE3864608D1 (de) Hmg-coa-reduktasehemmer.
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE253361T1 (de) Mittel zur gesteuerten freisetzung von paroxetin
DE69007223D1 (de) Verfahren und zusammensetzung von geprägten schuhsohlen.
DE68927160D1 (de) Verwendung von N-Butyl-Deoxynojirimycin zur Behandlung von Herpes
ATE174895T1 (de) Aromatische inhibitoren von acetylcholinesterase
ATE212336T1 (de) Auflösungsverfahren von threo-methylphenidate
ATE87918T1 (de) Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
NO992296D0 (no) FremgangsmÕte for disubstituerte pyridiner
DE59604829D1 (de) Kontinuierliches Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethylpiperidin
ATE185969T1 (de) Potenzierung von nmda-antagonisten
DE69625069D1 (de) Insektizide von n-(substituiertes arylmethyl)-4-(bis (substituiertes phenyl oder pyridyl)methyl)-piperidin.
ATE97803T1 (de) Therapeutische verwendung von 5-ht3-rezeptorantagonisten.
DE59809538D1 (de) Verfahren zur Herstellung von 1,2,3,6-Tetrahydro-2,2,6,6-tetramethylpyridin
CA1262906C (en) 3-(2-FUROYL)-5-ALCOXYCARBONYL-2,6-DIMETHYL-4-(2-NITROPHENYL)-1,4-DIHYDROPYRIDINES, CALCIUM ANTAGONISTS
DE3884430D1 (de) Herstellungsverfahren von chlorierten olefinen.
ATE102449T1 (de) Verfahren und zusammensetzung von gepraegten schuhsohlen.
DE59607272D1 (de) Verfahren zum unterfangen von bauwerken
MX9604731A (es) Uso de un antagonista de peptidoleucotrieno y una antihistamina y composicion que los contiene.
NL1003243C2 (nl) (-)-(3R)-3-methyl-4-{4-£4-(4-pyridyl)piperazine-1-yl|-fenoxy}boterzuur.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification